BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2020

View Archived Issues

Grant supports Epsilogen's development of cancer immunotherapeutic EPS-201

Read More

Targeting periphery could be viable approach in ALS

Read More

Ideaya and the Broad Institute partner to advance synthetic lethality programs

Read More

GlaxoSmithKline patents hSTING agonists

Read More

Kowa discloses CSF-1R inhibitors

Read More

TaiwanJ Pharmaceuticals presents new ENPP2 and HDAC dual inhibitors

Read More

Tera Stone synthesizes new compounds for cancer

Read More

Researchers discover new CNKs as antitumoral agents

Read More

FDA clears IND application for first-in-human study of ADI-001

Read More

Ionis initiates phase I/II study of ION-541 to treat broad ALS population

Read More

First-in-human data presented for JAK3 inhibitor TD-5202

Read More

Lp-PLA2 inhibition may limit cardiovascular damage from radiotherapy

Read More

FDA approves Veklury for patients with COVID-19 requiring hospitalization

Read More

Galera initiates phase I/II GRECO-1 study of GC-4711 plus SBRT in NSCLC

Read More

FDA issues complete response letter for Qtrypta

Read More

Preclinical data presented on intranasal oxytocin formulation for IBS

Read More

SGX-301 continues to demonstrate positive benefits in phase III FLASH study

Read More

ProTrans approved for clinical trials in patients with COVID-19

Read More

New phase II trial investigates PT-112 for metastatic CRPC

Read More

SARS-CoV-2 vaccine BBIBP-CorV safe and induces humoral responses in phase I/II study

Read More

bit.bio and London Institute for Mathematical Sciences partner on production of human cells

Read More

Adalimumab s.c. efficacious and safe option for children with ulcerative colitis

Read More

Altered cathepsin K secretion contributes to congenital heart defects in a model of mucolipidosis II

Read More

Phase III studies of a quadrivalent virus-like particle influenza vaccine manufactured in plants

Read More

AstraZeneca initiates phase III trial of monalizumab in recurrent or metastatic SCCHN

Read More

Tetra reports findings with ARDS-003 in induced pulmonary fibrosis model

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing